ReShape Lifesciences
ReShape Lifesciences is a U.S. medical device company developing vagus nerve modulation (vBloc) systems, FDA-approved bariatric products (Lap-Band, Obalon), and—via distribution—neuromuscular rehabilitation devices, serving obesity, metabolic disease, and stroke-recovery patients in the U.S. and Canada.
- Company typePublic
- Founded2002
- HeadquartersIrvine, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ReShape Lifesciences does
ReShape Lifesciences Inc. is a U.S.-based medical device company, headquartered in Irvine, California and founded in 2002, focused on technologies for obesity, metabolic disease, and—more recently—neuromuscular rehabilitation. Its core technology is vagus nerve modulation (vBloc), a proprietary approach that delivers programmed electrical signals through implanted electrodes and a pulse generator to treat obesity and Type 2 diabetes; the lead embodiment, the Diabetes Bloc-Stim Neuromodulation System, holds 63 issued or pending patents globally and an Australian patent (No. 2019252920) protecting the technology until April 12, 2039. The commercial product portfolio spans the FDA-approved Lap-Band FLEX adjustable gastric band, the Obalon swallowable gastric balloon system (acquired from Obalon Therapeutics in 2021), calibration tubes used in laparoscopic bariatric surgery, and—via an exclusive U.S. distribution agreement with Motion Informatics announced in September 2025—the FDA-cleared Stimel-03 neuromuscular rehabilitation device and the AI/AR-enabled Spatial StimelMD system for stroke and post-surgical recovery.
ReShape generates revenue exclusively through hardware sales of medical devices, distributed through a small set of channel partners including Medtimo for Lap-Band, Obalon, and rehabilitation products, and Motion Informatics for Stimel-03 and Spatial StimelMD in the United States. Its customer base is segmented by use case—obesity and metabolic health patients (primary), and neurological rehabilitation patients (secondary)—with no disclosed direct-to-consumer model and no publicly disclosed pricing. Operating geographies are limited to the United States and Canada, and the company runs on a small staff of 11–50 employees with a lean cost base, having executed a strategic headcount reduction in June 2025 targeting over $750,000 in annual savings. Between February 2023 and June 2025, ReShape completed four public equity offerings totaling approximately $21.8 million to fund operations, alongside NIH SBIR grants totaling $900,000 for diabetes neuromodulation research. In August 2025, ReShape merged with Vyome Therapeutics to form Vyome Holdings (Nasdaq: HIND), divested its diabetes neuromodulation assets to Biorad Medisys for continued clinical development, and is now positioned as a subsidiary of a public biotech rather than an independent device company.
ReShape Lifesciences firmographics
Firmographics- Name
- ReShape Lifesciences
- Legal name
- ReShape Lifesciences Inc.
- Website
- https://reshapelifesciences.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ReShape Lifesciences is a U.S. medical device company developing vagus nerve modulation (vBloc) systems, FDA-approved bariatric products (Lap-Band, Obalon), and—via distribution—neuromuscular rehabilitation devices, serving obesity, metabolic disease, and stroke-recovery patients in the U.S. and Canada.
- Ownership category
- akta.pro rank
ReShape Lifesciences industry classification
Industry- Product category
- Medical Devices for Obesity and Metabolic Disease
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where ReShape Lifesciences is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Markets served
ReShape Lifesciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Others
Revenue model
- Medical Device Sales: Sale of FDA-approved weight loss and metabolic health medical devices including gastric balloons and vagus nerve modulation devices for obesity and diabetes treatment.
- Distribution Revenue: Revenue generated from distribution of rehabilitation medical devices through exclusive channel partnerships in the U.S. market.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
ReShape Lifesciences product offering
Product offeringCore offering
ReShape Lifesciences develops and commercializes FDA-approved medical devices for the treatment of obesity, metabolic diseases, and neuromuscular rehabilitation. Its portfolio includes the Lap-Band FLEX adjustable gastric band system, the Obalon swallowable gastric balloon, the investigational Diabetes Bloc-Stim Neuromodulation device using vBloc vagus nerve modulation technology, and distributed neurorehabilitation products (STIMEL-03 and Spatial StimelMD) marketed through exclusive U.S. distribution partners.
Product overview
ReShape Lifesciences offers a portfolio of FDA-approved medical devices focused on obesity treatment and metabolic health, including the Lap-Band FLEX adjustable gastric band system and the investigational Diabetes Bloc-Stim Neuromodulation device leveraging vBloc vagus nerve modulation technology. The company has expanded into neurorehabilitation through an exclusive U.S. distribution agreement for Motion Informatics' AI-enabled Spatial StimelMD system and the FDA-cleared STIMEL-03 neuromuscular rehabilitation device combining electrical stimulation with EMG biofeedback. The product portfolio spans surgical bariatric solutions (Lap-Band, Calibration Tubes), non-surgical weight loss options (Obalon gastric balloon), metabolic disease management (Diabetes Neuromodulation), and stroke/neuromuscular rehabilitation (STIMEL-03, Spatial StimelMD), supported by 63 issued or pending patents across vagal neuromodulation, glucose regulation, AI, and Bluetooth-enabled applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Lap-Band FLEX
Quantifiable outcome
- NIH SBIR grant funding of $331,541 awarded for diabetes device research
- +1 more outcomes
Companies that use ReShape Lifesciences
Customer profileSegments2 records
Ideal customer profiles2 records
ReShape Lifesciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ReShape Lifesciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Motion InformaticscoreReShape Lifesciences entered an exclusive U.S. distribution agreement with Motion Informatics to market the FDA-cleared Stimel-03, a neuromuscular rehabilitation device combining Functional Electrical Stimulation, Neuromuscular Electrical Stimulation, and real-time EMG biofeedback. The partnership expands ReShape's portfolio beyond weight-loss and metabolic health solutions into neurorehabilitation.
- Vyome TherapeuticsflagshipReShape Lifesciences merged with Vyome Therapeutics to form Vyome Holdings, a biotech company focused on immuno-inflammatory and rare diseases. The combined entity began trading on Nasdaq under the ticker HIND on India's Independence Day.
- Biorad MedisyscoreReShape Lifesciences entered an asset purchase agreement with Biorad Medisys. Biorad Medisys acquired assets from ReShape and is developing an implantable device using vagus nerve stimulation technology for diabetes management, with plans to begin human trials by end of next year.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
ReShape Lifesciences competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is a broad incumbent with adjacent franchises including InterStim sacral neuromodulation, diabetes management (MiniMed), and bariatric/metabolic surgical tools. Its scale, R&D resources, and direct hospital sales force make it a benchmark for any neuromodulation or metabolic disease device competitor.
Direct peers
- electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) technology (gammaCore) for headache and respiratory conditions, using the same vagus nerve mechanism as ReShape's vBloc technology. Both companies apply cervical vagus nerve stimulation to treat chronic disease through neuromodulation.
- Apollo Endosurgery: Apollo Endosurgery (acquired by Boston Scientific in 2023) was the most direct competitor in the U.S. bariatric device market, commercializing the Orbera intragastric balloon and overlapping Lap-Band product lines. Both companies targeted the same obesity-treatment patient population with minimally invasive surgical devices.
- Allurion Technologies: Allurion markets a swallowable, procedure-less gastric balloon for weight loss, directly competing with ReShape's Obalon balloon. Both companies address patients seeking non-surgical obesity interventions through temporary intragastric balloon technology.
- Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostimulator for obstructive sleep apnea, sharing ReShape's core competency of implant-driven electrical stimulation therapy. Both companies sell FDA-cleared implanted neuromodulation devices to physician specialists through a focused commercial model.
- Helius Medical Technologies: Helius Medical Technologies markets the Portable Neuromodulation Stimulator (PoNS) for neurological rehabilitation following mild-to-moderate traumatic brain injury, overlapping with ReShape's STIMEL-03 and Spatial StimelMD neurorehabilitation product line. Both target post-stroke and neurological recovery patient populations.
Emerging players
- Spatz FGIA: Spatz FGIA develops the Spatz3 adjustable gastric balloon, competing directly with ReShape's Obalon in the non-surgical weight loss balloon category. Both companies offer temporary intragastric balloons targeting patients seeking less invasive alternatives to bariatric surgery.
- GI Dynamics: GI Dynamics developed the EndoBarrier gastrointestinal liner, an endoscopic bariatric device for Type 2 diabetes and obesity, closely overlapping ReShape's metabolic disease treatment mission. Both companies pursued minimally invasive endoscopic approaches to treat obesity and related metabolic conditions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
ReShape Lifesciences social profiles
Digital presenceReShape Lifesciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReShape Lifesciences leadership team
Management profileNumber of profiles
Profiles5 records
ReShape Lifesciences funding detail
Funding detailFunding overview
Funding rounds19 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReShape Lifesciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReShape Lifesciences
What does ReShape Lifesciences do?
ReShape Lifesciences develops and commercializes FDA-approved medical devices for the treatment of obesity, metabolic diseases, and neuromuscular rehabilitation. Its portfolio includes the Lap-Band FLEX adjustable gastric band system, the Obalon swallowable gastric balloon, the investigational Diabetes Bloc-Stim Neuromodulation device using vBloc vagus nerve modulation technology, and distributed neurorehabilitation products (STIMEL-03 and Spatial StimelMD) marketed through exclusive U.S. distribution partners.
Is ReShape Lifesciences a public or private company?
ReShape Lifesciences is a public company. It is classified as public and is currently operating.
When was ReShape Lifesciences founded?
ReShape Lifesciences was founded in 2002. It employs 11 to 50 people.
Where is ReShape Lifesciences based?
ReShape Lifesciences is headquartered in Irvine, United States, in the North America region.
How does ReShape Lifesciences make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Revenue.
Who are ReShape Lifesciences's main competitors?
Medtronic is listed as a broad incumbent. Direct peers are electroCore, Apollo Endosurgery, Allurion Technologies, Inspire Medical Systems and Helius Medical Technologies. Emerging players are Spatz FGIA and GI Dynamics.
Does ReShape Lifesciences have an API?
No public API is recorded for ReShape Lifesciences.
What industry is ReShape Lifesciences in?
ReShape Lifesciences's product category is Medical Devices for Obesity and Metabolic Disease. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 339112 and its SIC code is 3841.